This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Canceled)

2. (Currently Amended) A compound of Formula I

$$A - D - B \qquad (I)$$

or a pharmaceutically acceptable salt thereof, wherein:

D is -NH-C(O)-NH-,

A is of the formula: $-L-(M-L^1)_q$, where

L is substituted or unsubstituted phenyl bound directly to D,

L^1 is phenyl substituted by $-C(O)R_x$, **or** pyridinyl substituted by $-C(O)R_x$, ~~**or isoindoline,**~~

M is oxygen,

q is 1 and

B is a substituted or unsubstituted pyridyl group, a substituted or unsubstituted quinolinyl group or a substituted or unsubstituted isoquinolinyl group,

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;

R_x is NR_aR_b where R_a and R_b are,

a) independently hydrogen, C_1-C_{10} alkyl, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, phenyl, pyridinyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, substituted C_{1-10} alkyl, substituted C_{3-10} cycloalkyl, substituted phenyl, substituted pyridinyl, substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl, where R_a and R_b are a substituted group, they are substituted by halogen up to per halo, hydroxy, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, phenyl, pyridinyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, halo-substituted C_{1-6} alkyl up to per halo alkyl,

halo-substituted phenyl up to per halo phenyl, halo-substituted pyridinyl, up to per halo pyridinyl, halo-substituted morpholinyl, up to per halo morpholinyl, halo-substituted piperidinyl, up to per halo piperidinyl, halo-substituted pyrrolidinyl, up to per halo pyrrolidinyl, or halo-substituted tetrahydrofuryl up to per halo tetrahydrofuryl,

each W is independently -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl, phenyl, pyridinyl, pyrazolyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, or tetrahydrofuryl, substituted C_1-C_{10} alkyl, substituted C_1-C_{10} alkoxy, substituted C_2-C_{10} alkenyl, substituted C_1-C_{10} alkenoyl, substituted C_3-C_{10} cycloalkyl substituted phenyl, substituted pyridinyl, substituted pyrazolyl substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl,

where W is a substituted group, it is substituted by one or more substituents which are each, independently, -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ or halogen,

each R^7 is independently H, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl, phenyl or pyridinyl up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl or up to per-halosubstituted phenyl.

3. (Canceled)

4. (Previously Presented) A compound as in claim 2 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

5. (Previously Presented) A compound of claim 2 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or substituted isoquinolinyl group substituted 1 to 3 times by one or more substituents which are each, independently, -CN, halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -OH, up to per halo substituted C_1-C_{10}

alkyl, up to per halo substituted C_1-C_{10} alkoxy or phenyl substituted by halogen up to per halo.

6. **(Canceled)**

7. **(Canceled)**

8. **(Canceled)**

9. **(Canceled)**

10. **(Canceled)**

11. **(Canceled)**

12. **(Previously Presented)** A compound of claim 2 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents which are each, independently, C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy or up to per halo substituted C_1-C_{10} alkoxy.

13. **(Canceled)**

14. **(Canceled)**

15. **(Previously Presented)** A compound of claim 2 wherein L^1 is substituted only by $-C(O)R_x$.

16. **(Previously Presented)** A compound of claim 2 wherein L^1 is substituted by $-C(O)R_x$ wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or C_1 - C_{10} alkyl.

17. **(Canceled)**

18. **(Canceled)**

19. **(Canceled)**

20. **(Canceled)**

21. **(Canceled)**

22. **(Canceled)**

23. **(Canceled)**

24. **(Canceled)**

25. **(Previously Presented)** A compound of claim 2 which is a pharmaceutically acceptable salt of a compound of formula I which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; and

b) an acid salt of an organic or inorganic base containing a cation which is an alkaline cation, alkaline earth cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

26. **(Canceled)**

27. **(Previously Presented)** A pharmaceutical composition comprising a compound of Formula I of claim 2 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

28. **(Canceled)**

29. **(Cancelled)**

30. **(Canceled)**

31. **(Canceled)**

32. **(Canceled)**

33. **(Canceled)**

34. **(Previously Presented)** A compound which is



















or a pharmaceutically acceptable salt thereof.

35. (Previously presented) A pharmaceutical composition comprising a compound which is



















or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.

36. (Previously Presented) A method for treating colorectal cancer in a host, comprising administering to a host in need thereof an effective amount of a compound which is



















or a pharmaceutically acceptable salt thereof.

37. **(Previously Presented)** A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is of the formula: -L-(M-L^1)$_q$, where L is phenyl bound directly to D, L^1 is pyridinyl, M is oxygen and q is 1; and

B is a substituted or unsubstituted pyridyl, quinolinyl or isoquinolinyl group,

wherein L^1 is substituted by -C(O)R_x,

R_x is NR_aR_b where R_a and R_b are independently hydrogen or C_1-C_{10} alkyl,

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;

wherein each W is independently -CN, -CO_2R^7, -C(O)NR^7R^7, -C(O)-R^7, -NO_2, -OR^7, -SR^7, -NR^7R^7, -NR^7C(O)OR^7, -NR^7C(O)R^7, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl, phenyl, pyridinyl, pyrazolyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, substituted C_1-C_{10} alkyl, substituted C_1-C_{10} alkoxy, substituted C_2-C_{10} alkenyl, substituted C_1-C_{10} alkenoyl, substituted C_3-C_{10} cycloalkyl substituted phenyl, substituted pyridinyl, substituted pyrazolyl substituted piperazinyl, substituted morpholinyl, substituted piperidinyl, substituted pyrrolidinyl, or substituted tetrahydrofuryl, where W is a substituted group, it is substituted by one or more substituents which are each, independently, -CN, -CO_2R^7, -C(O)R^7, -C(O)NR^7R^7, -OR^7, -SR^7, -NR^7R^7, -NO_2, -NR^7C(O)R^7, -NR^7C(O)OR^7 or halogen,

38. (Canceled)

39. (Previously Presented) A compound as in claim 37 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

40. (Previously Presented) A compound of claim 37 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or isoquinolinyl group substituted 1 to 3 times by 1 or more substituents which are each independently -CN, halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -OH, up to per halo substituted C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkoxy or phenyl substituted by halogen up to per halo.

41. (Canceled)

42. (Previously Presented) A compound of claim 37 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents which are each, independently, C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy or up to per halo substituted C_1-C_{10} alkoxy.

43 (Canceled)

44, (Canceled)

45. (Previously Presented) A compound as in claim 37 wherein substituents for B and L and additional substituents for L^1, are each, independently, C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy or up to per halo substituted C_1-C_{10} alkoxy.

46. (Previously Presented) A compound of claim 37 which is a pharmaceutically acceptable salt of a compound of formula I which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; and

b) an acid salt of an organic or inorganic base containing a cation which is an alkaline cation, alkaline earth cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

47. (Previously presented) A pharmaceutical composition comprising a compound of claim 37 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

48. (cancelled)

49. (cancelled)